Free Trial
NASDAQ:RANI

Rani Therapeutics Q1 2025 Earnings Report

Rani Therapeutics logo
$0.53 -0.01 (-0.94%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$0.52 -0.01 (-0.95%)
As of 08/8/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rani Therapeutics EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.22
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Rani Therapeutics Revenue Results

Actual Revenue
$0.20 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rani Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
9:30AM ET

Rani Therapeutics Earnings Headlines

Rani Therapeutics Holdings, Inc. (RANI) - Yahoo Finance
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
See More Rani Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rani Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rani Therapeutics and other key companies, straight to your email.

About Rani Therapeutics

Rani Therapeutics (NASDAQ:RANI) operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

View Rani Therapeutics Profile

More Earnings Resources from MarketBeat